Get the Stockscreener App
135.50
1.26%
1.68
After Hours:
135.12
-0.38
-0.28%
Transmedics Group Inc stock is traded at $135.50, with a volume of 814.53K.
It is up +1.26% in the last 24 hours and down -5.49% over the past month.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
See More
Previous Close:
$133.82
Open:
$135.33
24h Volume:
814.53K
Relative Volume:
1.10
Market Cap:
$4.63B
Revenue:
$531.29M
Net Income/Loss:
$71.66M
P/E Ratio:
70.07
EPS:
1.9338
Net Cash Flow:
$17.35M
1W Performance:
+1.65%
1M Performance:
-5.49%
6M Performance:
+7.84%
1Y Performance:
+80.62%
1-Day Range:
$132.78
$136.41
1-Week Range:
$127.50
$137.49
52-Week Range:
$62.07
$156.00
Transmedics Group Inc Stock (TMDX) Company Profile
Name
Transmedics Group Inc
Sector
Industry
Phone
(978) 552-0900
Address
200 MINUTEMAN ROAD, ANDOVER, MA
Compare TMDX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TMDX
Transmedics Group Inc
|
135.50 | 4.57B | 531.29M | 71.66M | 17.35M | 1.9338 |
|
ABT
Abbott Laboratories
|
113.29 | 195.21B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
377.32 | 141.28B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
98.49 | 123.60B | 35.48B | 4.64B | 5.41B | 3.5856 |
|
BSX
Boston Scientific Corp
|
76.28 | 113.14B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
78.98 | 45.52B | 6.07B | 1.06B | 799.60M | 1.8527 |
Transmedics Group Inc Stock (TMDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-23-25 | Upgrade | Needham | Hold → Buy |
| Oct-13-25 | Initiated | Jefferies | Buy |
| Sep-16-25 | Initiated | Evercore ISI | Outperform |
| Sep-04-25 | Initiated | Stifel | Hold |
| Dec-17-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-22-24 | Downgrade | Needham | Buy → Hold |
| Oct-29-24 | Reiterated | Needham | Buy |
| Oct-29-24 | Reiterated | Oppenheimer | Outperform |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Aug-21-24 | Initiated | Needham | Buy |
| Jun-06-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-04-24 | Initiated | Stephens | Overweight |
| Mar-28-24 | Initiated | Piper Sandler | Overweight |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Aug-02-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-08-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-07-20 | Initiated | Oppenheimer | Outperform |
| May-28-19 | Initiated | Canaccord Genuity | Buy |
| May-28-19 | Initiated | Cowen | Outperform |
| May-28-19 | Initiated | JP Morgan | Overweight |
| May-28-19 | Initiated | Morgan Stanley | Equal-Weight |
View All
Transmedics Group Inc Stock (TMDX) Latest News
The Bull Case For TransMedics Group (TMDX) Could Change Following Full FDA Approval Of ENHANCE Heart Trial - Yahoo Finance
A Look At TransMedics Group (TMDX) Valuation After Full FDA Approval For Next Generation OCS Heart Trial - Yahoo Finance
What Catalysts Are Reframing The TransMedics Group (TMDX) Narrative Now - Yahoo Finance
FDA Greenlights TransMedics ENHANCE Heart Trial Shaping Growth Prospects - Yahoo Finance
How to watch TransMedics' March investor events online - Stock Titan
TransMedics Group (TMDX) to Release Quarterly Earnings on Tuesday - MarketBeat
TransMedics Group, Inc. (TMDX) Stock Analysis: Unlocking a 11% Upside in the Medical Device Sector - DirectorsTalk Interviews
Understanding the Setup: (TMDX) and Scalable Risk - Stock Traders Daily
TMDX Wins Full FDA IDE Approval for Next-Gen OCS ENHANCE Heart Trial - Zacks Investment Research
Bastion Asset Management Inc. Purchases New Stake in TransMedics Group, Inc. $TMDX - MarketBeat
TransMedics Group Inc (NASDAQ:TMDX) Screened as a High-Momentum Growth Stock - ChartMill
Public Sector Pension Investment Board Raises Position in TransMedics Group, Inc. $TMDX - MarketBeat
How Investors May Respond To TransMedics Group (TMDX) Full IDE Approval For ENHANCE Heart Trial - simplywall.st
Wall Street Zen Upgrades TransMedics Group (NASDAQ:TMDX) to Buy - MarketBeat
Will TransMedics Group Inc. outperform the market in YEARBuy Signal & Weekly High Potential Stock Alerts - mfd.ru
Bronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Investors to Inquire about Securities Investigation - ACCESS Newswire
Is Now An Opportune Moment To Examine TransMedics Group, Inc. (NASDAQ:TMDX)? - Yahoo Finance
How Do Investors Really Feel About TransMedics Group Inc? - Benzinga
Big Money Moves: What makes TransMedics Group Inc stock attractive todayMarket Rally & Fast Exit and Entry Trade Guides - baoquankhu1.vn
What Is TransMedics Group, Inc.'s (NASDAQ:TMDX) Share Price Doing? - 富途牛牛
TransMedics to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - Sahm
TransMedics receives full FDA approval for heart transplant trial - Investing.com Nigeria
TransMedics receives full FDA approval for heart transplant trial By Investing.com - Investing.com Australia
TransMedics (TMDX) Secures FDA Approval for Advanced Heart Device Trial - GuruFocus
TransMedics receives full and unconditional FDA IDE approval for next-generation OCS Heart Enhance trial - marketscreener.com
TransMedics' 650+ patient heart transplant trial gets full FDA go-ahead - Stock Titan
TransMedics Receives Full and Unconditional FDA IDE Approval for Next-Generation OCS Heart ENHANCE Trial - Sahm
New York State Common Retirement Fund Sells 134,406 Shares of TransMedics Group, Inc. $TMDX - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Stockholders to Reach Out - ACCESS Newswire
Seaport Research to Host Virtual Meeting Focusing on TMDX - GuruFocus
Renaissance Group LLC Acquires Shares of 76,078 TransMedics Group, Inc. $TMDX - MarketBeat
Principal Financial Group Inc. Purchases 53,995 Shares of TransMedics Group, Inc. $TMDX - MarketBeat
TD Cowen Sticks to Its Buy Rating for TransMedics Group (TMDX) - The Globe and Mail
TransMedics Group Names New Commercial Leader - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Stockholders to Connect - ACCESS Newswire
Commit To Buy TransMedics Group At $80, Earn 16.2% Using Options - Nasdaq
Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), UnitedHealth (UNH) and Johnson & Johnson (JNJ) - The Globe and Mail
TransMedics Group Inc (NASDAQ:TMDX): A GARP Stock with Strong Growth at a Fair Price - ChartMill
Up 95% In Last 12 Months, Can TransMedics Stock Keep Climbing In 2026? - TIKR.com
TransMedics Group, Inc. (TMDX): A Bull Case Theory - Finviz
Brown Capital Management LLC Reduces Stock Position in TransMedics Group, Inc. $TMDX - MarketBeat
TransMedics: Italian NOP Program Reinforces Huge International Opportunity (NASDAQ:TMDX) - Seeking Alpha
Reasons to retain TransMedics stock in your portfolio for now - MSN
TransMedics Group, Inc. (TMDX) Stock Analysis: Exploring Growth Potential Amidst Robust Revenue Surge In Medical Devices - DirectorsTalk Interviews
These 10 Stocks Could Be Short Squeeze Targets: Lucid, Kohl's, Avis and More - Benzinga
TransMedics Group Inc (NASDAQ:TMDX) Shows Strong Growth Momentum and Technical Setup - ChartMill
Lisanti Capital Growth LLC Grows Stock Holdings in TransMedics Group, Inc. $TMDX - MarketBeat
TransMedics Group Inc. (NASDAQ:TMDX) Combines Strong Growth with Bullish Technical Momentum - ChartMill
TransMedics Group (NASDAQ:TMDX) Downgraded to "Hold" Rating by Wall Street Zen - MarketBeat
TransMedics Group Inc (TMDX) Shares Gap Down to $133.5 on Jan 30 - GuruFocus
Assessing TransMedics Group (TMDX) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
Transmedics Group Inc Stock (TMDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):